At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BOLD: A Trial of Blood Pressure Lowering in Dialysis
In Brief
A Phase 2 clinical trial evaluating Anti-Hypertensive medications and Dry Weight Adjustment for Blood Pressure and 3 related conditions. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
Blood pressure may be one of the most important modifiable risk factors for cardiovascular disease in patients with end-stage-renal-disease undergoing maintenance hemodialysis. Although a systolic blood pressure \<140 mmHg treatment target has been recommended, there remains uncertainty on which blood pressure should be targeted, more specifically that measured in the dialysis unit or at home. Observational studies have reported a paradoxical U-shaped associated with dialysis unit (pre-dialysis) systolic blood pressure and cardiovascular events and death (where blood pressure below 140 mmHg is actually linked with poor outcomes). Conversely, the same studies have reported a linear association between higher home systolic blood pressure and worse clinical outcomes, where blood pressure below 140 mmHg is associated with better outcomes. This pilot clinical trial aims to address this important question.
Study Details
Timeline
Interventions
Use of standard Anti-Hypertensive medications
The participant's target post-dialysis dry weight is adjusted